Skip to main content
PLOS One logoLink to PLOS One
. 2023 May 17;18(5):e0285612. doi: 10.1371/journal.pone.0285612

Age-specific SARS-CoV-2 infection fatality rates derived from serological data vary with income and income inequality

Chloe G Rickards 1,*, A Marm Kilpatrick 1,*
Editor: Junyuan Yang2
PMCID: PMC10191265  PMID: 37196049

Abstract

The ongoing COVID-19 pandemic has killed at least 1.1 million people in the United States and over 6.7 million globally. Accurately estimating the age-specific infection fatality rate (IFR) of SARS-CoV-2 for different populations is crucial for assessing and understanding the impact of COVID-19 and for appropriately allocating vaccines and treatments to at-risk groups. We estimated age-specific IFRs of wild-type SARS-CoV-2 using published seroprevalence, case, and death data from New York City (NYC) from March to May 2020, using a Bayesian framework that accounted for delays between key epidemiological events. IFRs increased 3-4-fold with every 20 years of age, from 0.06% in individuals between 18–45 years old to 4.7% in individuals over 75. We then compared IFRs in NYC to several city- and country-wide estimates including England, Switzerland (Geneva), Sweden (Stockholm), Belgium, Mexico, and Brazil, as well as a global estimate. IFRs in NYC were higher for individuals younger than 65 years old than most other populations, but similar for older individuals. IFRs for age groups less than 65 decreased with income and increased with income inequality measured using the Gini index. These results demonstrate that the age-specific fatality of COVID-19 differs among developed countries and raises questions about factors underlying these differences, including underlying health conditions and healthcare access.

Introduction

As of January 5, 2023, COVID-19 has killed at least 1.1 million people in the US and over 6.7 million globally [1]. The infection fatality rate (IFR)–the chance of dying after becoming infected–is a crucial metric for understanding the disease severity of SARS-CoV-2 [28]. Accurate age-specific IFRs are needed to allocate limited supplies of vaccines, respirators, ICU beds, and anti-viral drugs to minimize mortality from COVID-19 [9,10].

Accurately estimating COVID-19 IFRs requires both quantification of the total number of infections (including undetected asymptomatic and mildly symptomatic infections), and accounting for delays between infection and death [11,12]. First, quantifying the total number of infections is usually done using serosurveys. Accurate IFR estimates require relatively unbiased serosurveys that sample the full population at risk of infection [13]. Second, deaths due to COVID-19 occur within a wide time period after initial infection, (on average, 20.2 days (95% CI 8.0–50.0 [11] after exposure). This time period can be broken down into several smaller delays [11], including the incubation period [14], the delay between symptom onset and case reporting [15], and the delay between case reporting and death [11]. Accurately estimating IFRs requires properly accounting for these delays, as well as the delay between infection and mounting detectable antibodies (seroconversion).

Previous studies of age-specific IFRs for COVID-19 have found a log-linear increase in IFR with age [28], except for elevated deaths in very young children. Above 18 years of age, there was a 0.6% increase in IFR with every five years of age [4]. However, there were substantial differences in age-specific IFRs estimates among countries [4,12]. For example, the oldest age groups in Sweden experienced an IFR up to 5 times higher than the oldest groups in Mexico [16,17]. This indicates the need for population-specific age-based IFR estimates when considering the mortality impacts of COVID-19 on a specific community and when assessing potential contributing factors towards increased fatality rates. While the contribution of poverty to COVID-19 mortality has been repeatedly demonstrated [18,19], it is not clear if poverty increases the risk of exposure, the risk of death following infection (the IFR), or both. Surprisingly there have been no age-specific IFR estimates derived solely from a population-based serosurvey of a US population, nor has there been a rigorous comparison of serosurvey-based age-specific IFR estimates between global populations.

We estimated age-specific IFRs using data from a seroprevalence study conducted in New York City shortly after the peak of the spring 2020 epidemic [20], publicly available case and death records [21], and Bayesian inference to account for delays between infection, symptom onset, case ascertainment, death and seroconversion [11]. We then compared these to other IFR estimates that were based on relatively unbiased serosurveys to see if and how age-specific COVID-19 mortality patterns in New York City differed from other populations around the world. Finally, we correlated age-specific IFR estimates from different populations with measures of income and income inequality, which might reflect access to health care.

Methods

We estimated IFRs using case counts and number of deaths from the New York City Department of Health and Mental Hygiene archive webpage for the dates 3/9/20 to 5/17/20 [21]. To quantify infections, we used data from a serosurvey in New York City conducted over a 10-day period (April 19–28, 2020), two-weeks after the peak in cases in Spring 2020 [20] (Fig 1). Survey participants for the serosurvey were recruited at grocery stores without prior advertisement to reduce bias [20]. The serosurvey was conducted through the entire state of New York, but we focused on New York City for several reasons: New York City had a higher overall seroprevalence (by about 1.5- to 6-fold) and sample size (by about 10-fold) [20], statewide seroprevalence was highly heterogenous [20], and New York City’s case and death reporting system is separate from the statewide reporting system [21,22]. Only New York City reported cases and deaths by age, whereas New York State did not, so age-specific IFR estimates were only possible with New York City data [21,22]. The New York City Department of Health and Mental Hygiene reported deaths in two categories: “confirmed” and “combined” (including probable and confirmed deaths). We calculated IFRs for each of these death categories.

Fig 1. Delay distributions between infection and key events in the progression of COVID-19.

Fig 1

Key events include symptom onset, case reporting, death, and seroconversion. The distribution of each delay is shown with a violin plot, and boxplots display the median, inter-quartile range (box), and 95% CI (whiskers).

To align the seroprevalence survey with reported deaths, we had to address mismatches in the age groups for the two datasets. The New York City serosurvey study reported data in 4 age groups: 18–34, 35–44, 45–54, and 55+ [20]. The New York City Department of Health and Mental Hygiene reported deaths in five age groups: 0–17, 18–44, 45–64, 65–74, and 75+ [21]. We estimated IFR values for the age classes used for deaths by the New York City Dept. of Health and Mental Hygiene. First, to estimate the seroprevalence for the 0–17 age class, which didn’t have a seroprevalence estimate from New York City [20], we estimated the seroprevalence ratio between the 0–17 age class and the 18–44 age class using a serosurvey from Spain, as this survey was one of the few that contained seroprevalence data for 0–17 year olds [23]. This ratio was 0.81, implying an estimated seroprevalence for 0–17 year-old individuals in New York City of 0.81 * 22.3% = 18.1% (8.96–29.8%). Second, we used the single seroprevalence estimate for individuals over the age of 55 [20] for the two oldest age classes used for reported deaths (64–75, and 75+) [21]. Finally, we used a population-weighted average of the 45–54 and 55+ seroprevalences for the 45–64 age class [20,24].

We estimated age-specific IFRs using a previously established Bayesian statistical framework [11], which combines seroprevalence estimates (including uncertainty in the estimates) with time series of cases and deaths [22] and delay distributions between key events [3,6,2527] (Fig 1; S1 Table). The scripts used to perform this inference are available on Github at https://github.com/ChloeRickards/sars-cov-2-ifr-nyc.

We compared the age-specific IFR estimates for New York City to seven other age-specific IFR estimates that were based on relatively unbiased serosurveys [6,11,16,17,28,29]. We excluded other IFR studies that were not based on population-representative serosurveys, did not properly account for the distribution of delays between infection, seroconversion and death, or did not have reliable case and death data available (see study-specific exclusion criteria in S2 Table). We also compared our estimates to a global age-specific IFR estimate [4]. We used IFR estimates from other studies that included care-home resident deaths because New York City also included care home deaths in their reporting.

Results

The New York City serosurvey took place in late April, in the latter third of the initial 2020 COVID-19 epidemic, when new cases per day had fallen to approximately half of the peak (Fig 2) [20]. The serosurvey found that 22.7% of the New York City population was seropositive and estimated that approximately 1.5 million infections had occurred [20]. By approximately mid-May, when the last deaths from infections detected in the serosurvey would have occurred, there were nearly 16,000 confirmed COVID-19 deaths (Table 1), and nearly 4,500 probable COVID-19 deaths (S3 Table).

Fig 2. COVID-19 timeline for New York City in Spring 2020.

Fig 2

The timeline includes confirmed cases, deaths and inferred infections over time, and the duration and midpoint date of the serosurvey. To facilitate display, infections divided by 10 are shown.

Table 1. Seroprevalence and infection fatality rate (IFR) estimates in New York City for five age classes, using confirmed COVID-19 deaths (excluding probable deaths).

Age class Population [24] Confirmed COVID-19
Deaths, as of May
17, 2020 [21]
Estimated Infection Prevalence [14] (95% CI) IFR (95% CI)
0–17 1,783,174 10 18.0 (8.96–29.8) 0.0015 (0.00038–0.0037)
18–44 3,493,918 625 22.4 (19.6–24.9) 0.063 (0.052–0.076)
45–64 2,112,562 3556 24.1 (21.8–26.4) 0.52 (0.43–0.61)
65–74 689,816 3963 21.5 (19.6–23.4) 1.9 (1.6–2.3)
75+ 551,853 7731 21.5 (19.6–23.4) 4.7 (3.9–5.6)

Age-specific IFRs for SARS-CoV-2 in New York City based on confirmed deaths increased logarithmically more than 75-fold from 0.06% in 18–44 to 4.7% in 75+ year-olds (Table 1). When including both confirmed and probable COVID-19 deaths, the IFRs were 22–36% higher across adult age classes (S3 Table).

IFRs from New York City for the 18–44 and 45–64 age classes were higher (with non-overlapping 95% confidence intervals) than corresponding IFRs for England [6], Switzerland [11], Belgium [29], Sweden [17], and the global estimate [4] (Figs 3 and S1). In contrast, the IFRs for the oldest two age classes, 65–74 and 75+ were lower (with non-overlapping 95% CIs) than IFRs from England, Switzerland, and the global baseline but were higher than corresponding IFRs from Belgium (Figs 2 and S2). Variation in IFRs among populations decreased with income (Fig 4) and increased with wealth inequality (S2 Fig), as quantified by the Gini index, for younger (18–44, 45–64), but not older (65+), age groups.

Fig 3. Age-specific infection fatality ratio (IFR) of COVID-19 on a log-scale (mean ± 95% CI).

Fig 3

Points are plotted at the midpoint of the age-class on the x-axis and are slightly jittered along the x-axis to facilitate presentation. Lines show age-specific IFRs for different populations, using only confirmed COVID-19 deaths where possible. This study is represented as “New York City” in red. IFR means and confidence intervals that estimate a value of 0 are represented as 0.001.

Fig 4. Infection fatality ratio (IFR) of COVID-19 plotted against median income for that country.

Fig 4

Data points shown for age groups (a) 18–44, (b) 45–64, (c) 65–74, and (d) 75+. Fitted lines show significant relationships where they exist. There were only three IFR estimates for the 0–17 age category so this age category was omitted from the plot.

Discussion

We found that IFRs in New York City showed similar log-linear increases with age as many other studies, but there were substantial differences among populations in IFRs, including New York City, for several age groups. The causes for differences in age-specific IFRs among countries are poorly understood [4], but could be due to differences in underlying conditions [19], genetics [30], or poverty and health care access [31], with evidence being limited for two of these three possibilities. First, several underlying health conditions, including obesity, diabetes, immunosuppression, and cancer increase a person’s risk of dying from COVID-19 [19], and in New York City, 79% of COVID-19 deaths in 18–44 year-olds, and 85% of deaths in 45–64 year-olds in New York City had pre-existing conditions. A future analysis could examine whether differences among populations in pre-existing conditions underly differences among population in COVID-19 age-specific IFRs. Second, although expression of some genes, like ace2, have been linked to both age and increased COVID-19 mortality [3234], it is unclear if expression of these genes differs among populations.

In contrast, we found correlations among some age-specific IFRs and both income and income inequality, and several other studies have found correlations between COVID-19 mortality and measures of poverty [18,19,31,35]. Studies of poverty and COVID-19 usually haven’t been able to separate exposure to SARS-CoV-2 from mortality once infected. As a result, it wasn’t previously possible to determine whether poverty led to higher SARS-CoV-2 exposure rates through larger household size, workplace exposure, or other factors, or whether poverty led to higher mortality given infection. Our results suggest that lower income is associated with higher mortality following infection for younger and middle age classes. This may reflect access to health care and medications, or underlying conditions that are exacerbated by poverty [36]. However, a lack of a relationship between income and income inequality and IFRs for the oldest age classes suggests that for these age groups other factors are more important than income.

One shortcoming of our study is that age and death data were only available in relatively wide age categories. For example, the oldest age class for the seroprevalence study was 55+ which combined parts of three age categories of the death data (45–64, 65–74, and 75+) which sometimes differ in SARS-CoV-2 infection [6]. Similarly, COVID-19 deaths for 18–44 year olds were combined into one group, despite variation in seroprevalence within this age group [6]. Reporting seroprevalence and deaths for finer age classes would enable more accurate estimates and a better understanding of the fatality of COVID-19 across age groups.

The COVID-19 pandemic has reshaped communities worldwide. We found substantial variation in age-specific infection fatality rates for COVID-19, both between richer and poorer countries and even within wealthier countries. This variation can have substantial consequences. For example, in addition to variation in mortality, COVID-19 deaths have led to millions of cases of caregiver death and orphanhood [37,38]. Notably, age-specific COVID-19 infection fatality rates were correlated with both income and income inequality, suggesting that the disproportionate effects of COVID-19 on poorer communities arose not only from higher exposure rates, but also from higher mortality following infection. A key goal in preparing for the next pandemic is reducing inequalities that contribute to these higher infection fatality rates.

Supporting information

S1 Fig. Age-specific infection fatality ratio (IFR) of COVID-19 (mean ± 95% CI) on an untransformed scale.

Points are plotted at the midpoint of the age class on the x-axis, and slightly jittered along the x-axis facilitate presentation. Lines show age-specific IFRs for different populations, using confirmed-only COVID-19 deaths where possible. This study is represented in red, as “New York City”. IFR means and confidence intervals that estimate a value of 0 are represented as 0.001. The upper bound on the 90+ class for Sweden extends to 29.5% but is represented here as 20%.

(PDF)

S2 Fig. Infection fatality ratio (IFR) of COVID-19 plotted against the Gini index [41].

Higher values of the Gini index represent higher levels of inequality. Fitted lines show significant relationships. Age classes include (a) 18–44, (b) 45–64, (c) 65–74, and (d) 75+. There were only three IFR estimates for the 0–17 age category so this age category was omitted from the plot.

(PDF)

S1 Table. Delay distributions and sources.

The delays from symptom onset to case reporting [27] and from case reporting to death [28] are specific to New York City. See Perez-Saez et al. [11] for additional methods on delay distributions.

(PDF)

S2 Table. Exclusion criteria for global age-specific IFR comparisons.

Serosurveys based on blood donors were not considered.

(PDF)

S3 Table. Seroprevalence and infection fatality rate (IFR) estimates in New York City for five age classes, using confirmed and probable COVID-19 deaths.

The last column notes the percent increase in the IFR comparing confirmed deaths to confirmed and probable deaths.

(PDF)

Acknowledgments

We thank the authors of Reference [11] for making their R code available which facilitated the analyses presented here. We thank members of the Kilpatrick lab for feedback.

Data Availability

All scripts and data files are available from a public Github repository at https://github.com/ChloeRickards/sars-cov-2-ifr-nyc.

Funding Statement

AMK received funding from the National Science Foundation Division of Environmental Biology, Grants DEB-1717498, and DEB 1911853. CR received funding from the National Science Foundation Graduate Research Fellowship Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020. May 1;20(5):533–4. doi: 10.1016/S1473-3099(20)30120-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020. Jun 1;20(6):669–77. doi: 10.1016/S1473-3099(20)30243-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020. Dec 1;35(12):1123–38. doi: 10.1007/s10654-020-00698-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021. Feb;590(7844):140–5. doi: 10.1038/s41586-020-2918-0 [DOI] [PubMed] [Google Scholar]
  • 5.Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020. Jul 10;369(6500):208–11. doi: 10.1126/science.abc3517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ward H, Atchison C, Whitaker M, Ainslie KE, Elliott J, Okell L, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults [Internet]. medRxiv; 2020. [cited 2022 Feb 28]. p. 2020.08.12.20173690. Available from: https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2 [Google Scholar]
  • 7.Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo-Iglesias J, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. BMJ. 2020. Nov 27;371:m4509. doi: 10.1136/bmj.m4509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Brazeau N, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Report 34: COVID-19 infection fatality ratio: estimates from seroprevalence [Internet]. Imperial College London; 2020. Oct [cited 2022 Mar 25]. Available from: http://spiral.imperial.ac.uk/handle/10044/1/83545. [Google Scholar]
  • 9.National Academies of Sciences, Engineering, and Medicine. Framework for Equitable Allocation of COVID-19 Vaccine [Internet]. Gayle H, Foege W, Brown L, Kahn B, editors. Washington, DC: The National Academies Press; 2020. [cited 2022 Feb 28]. 272 p. Available from: https://www.nap.edu/catalog/25917/framework-for-equitable-allocation-of-covid-19-vaccine. [PubMed] [Google Scholar]
  • 10.Burki T. The future of Paxlovid for COVID-19. Lancet Respir Med [Internet]. 2022. May 24 [cited 2022 Jun 23];0(0). Available from: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00192-8/fulltext. doi: 10.1016/S2213-2600(22)00192-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Perez-Saez J, Lauer SA, Kaiser L, Regard S, Delaporte E, Guessous I, et al. Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis. 2021. Apr 1;21(4):e69–70. doi: 10.1016/S1473-3099(20)30584-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Brazeau NF, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Estimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modelling. Commun Med. 2022. May 19;2(1):1–13. doi: 10.1038/s43856-022-00106-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.McConnell D, Hickey C, Bargary N, Trela-Larsen L, Walsh C, Barry M, et al. Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2. Int J Environ Res Public Health. 2021. Jan;18(9):4640. doi: 10.3390/ijerph18094640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020. Aug;20(8):911–9. doi: 10.1016/S1473-3099(20)30287-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Scire J, Nadeau S, Vaughan T, Brupbacher G, Fuchs S, Sommer J, et al. Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft. Swiss Med Wkly. 2020. May 4;150:w20271. doi: 10.4414/smw.2020.20271 [DOI] [PubMed] [Google Scholar]
  • 16.Torres-Ibarra L, Basto-Abreu A, Carnalla M, Torres-Alvarez R, Reyes-Sanchez F, Hernández-Ávila JE, et al. SARS-CoV-2 infection fatality rate after the first epidemic wave in Mexico. Int J Epidemiol. 2022. Feb 14;dyac015. doi: 10.1093/ije/dyac015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.The infection fatality rate of COVID-19 in Stockholm–Technical report. 30.
  • 18.Tian T, Zhang J, Hu L, Jiang Y, Duan C, Li Z, et al. Risk factors associated with mortality of COVID-19 in 3125 counties of the United States. Infect Dis Poverty. 2021. Jan 4;10(1):3. doi: 10.1186/s40249-020-00786-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020. Aug;584(7821):430–6. doi: 10.1038/s41586-020-2521-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020. Aug 1;48:23–29.e4. doi: 10.1016/j.annepidem.2020.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.COVID-19: Data Archive—NYC Health [Internet]. [cited 2022 Feb 28]. Available from: https://www1.nyc.gov/site/doh/covid/covid-19-data-archive.page.
  • 22.COVID-19 Data in New York [Internet]. Department of Health. [cited 2022 Jun 23]. Available from: https://coronavirus.health.ny.gov/covid-19-data-new-york.
  • 23.Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020. Aug 22;396(10250):535–44. doi: 10.1016/S0140-6736(20)31483-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.NYCdata | Population & Geography [Internet]. [cited 2022 Mar 25]. Available from: https://www.baruch.cuny.edu/nycdata/population-geography/pop-demography.htm.
  • 25.Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet. 2020. Aug 1;396(10247):313–9. doi: 10.1016/S0140-6736(20)31304-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Greene SK, McGough SF, Culp GM, Graf LE, Lipsitch M, Menzies NA, et al. Nowcasting for Real-Time COVID-19 Tracking in New York City: An Evaluation Using Reportable Disease Data From Early in the Pandemic. JMIR Public Health Surveill. 2021. Jan 15;7(1):e25538. doi: 10.2196/25538 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Thompson CN, Baumgartner J, Pichardo C, Toro B, Li L, Arciuolo R, et al. COVID-19 Outbreak—New York City, February 29–June 1, 2020. Morb Mortal Wkly Rep. 2020. Nov 20;69(46):1725–9. doi: 10.15585/mmwr.mm6946a2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Marra V, Quartin M. A Bayesian estimate of the early COVID-19 infection fatality ratio in Brazil based on a random seroprevalence survey. Int J Infect Dis. 2021. Oct 1;111:190–5. doi: 10.1016/j.ijid.2021.08.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Molenberghs G, Faes C, Verbeeck J, Deboosere P, Abrams S, Willem L, et al. Belgian COVID-19 Mortality, Excess Deaths, Number of Deaths per Million, and Infection Fatality Rates (9 March—28 June 2020) [Internet]. medRxiv; 2020. [cited 2022 Mar 27]. p. 2020.06.20.20136234. Available from: https://www.medrxiv.org/content/10.1101/2020.06.20.20136234v2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Velavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, et al. Host genetic factors determining COVID-19 susceptibility and severity. eBioMedicine. 2021. Oct 1;72:103629. doi: 10.1016/j.ebiom.2021.103629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hashim MJ, Alsuwaidi AR, Khan G. Population Risk Factors for COVID-19 Mortality in 93 Countries. J Epidemiol Glob Health. 2020. Sep;10(3):204–8. doi: 10.2991/jegh.k.200721.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Santesmasses D, Castro JP, Zenin AA, Shindyapina AV, Gerashchenko MV, Zhang B, et al. COVID-19 is an emergent disease of aging. Aging Cell. 2020;19(10):e13230. doi: 10.1111/acel.13230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Viveiros A, Gheblawi M, Aujla PK, Sosnowski DK, Seubert JM, Kassiri Z, et al. Sex- and age-specific regulation of ACE2: Insights into severe COVID-19 susceptibility. J Mol Cell Cardiol. 2022. Mar 1;164:13–6. doi: 10.1016/j.yjmcc.2021.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020. Jun;28(6):715–8. doi: 10.1038/s41431-020-0636-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kim SJ, Bostwick W. Social Vulnerability and Racial Inequality in COVID-19 Deaths in Chicago. Health Educ Behav. 2020. Aug 1;47(4):509–13. doi: 10.1177/1090198120929677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Braveman P, Gruskin S. Poverty, equity, human rights and health. Bull World Health Organ. 2003;7. [PMC free article] [PubMed] [Google Scholar]
  • 37.Hillis SD, Blenkinsop A, Villaveces A, Annor FB, Liburd L, Massetti GM, et al. COVID-19–Associated Orphanhood and Caregiver Death in the United States. Pediatrics. 2021. Dec 1;148(6):e2021053760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Unwin HJT, Hillis S, Cluver L, Flaxman S, Goldman PS, Butchart A, et al. Global, regional, and national minimum estimates of children affected by COVID-19-associated orphanhood and caregiver death, by age and family circumstance up to Oct 31, 2021: an updated modelling study. Lancet Child Adolesc Health. 2022. Apr 1;6(4):249–59. doi: 10.1016/S2352-4642(22)00005-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Junyuan Yang

20 Feb 2023

PONE-D-23-00943Age-specific SARS-CoV-2 infection fatality rates derived from serological data vary with income and income inequalityPLOS ONE

Dear Dr. Rickards,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 18,2023. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Junyuan Yang

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

" ext-link-type="uri" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf"

2. Thank you for including your ethics statement:  "N/A".   

a. For studies reporting research involving human participants, PLOS ONE requires authors to confirm that this specific study was reviewed and approved by an institutional review board (ethics committee) before the study began. Please provide the specific name of the ethics committee/IRB that approved your study, or explain why you did not seek approval in this case.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research. 

b. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This paper estimated age-specific IFRs using data from a seroprevalence study conducted in New York City shortly after the peak of the spring 2020 epidemic. Then compared these to other IFR estimates that were based on relatively unbiased serosurveys to see if and how age-specific COVID-19 mortality patterns in New York City differed from other populations around the world. Finally, it correlated age-specific IFR estimates from different populations with measures of income and income inequality, which might reflect access to health care. This is helpful to provide some suggestions about the problem of the allocation of medical resources. The author is expected to make subsequent modifications according to the requirements and specifications of the journal.

Reviewer #2: The infection fatality and the age of the patients have been described. However, the authors need to explain the infection fatality rate and its relation to the income inequality. The authors must segregate the countries referenced in to /based on income differences. The authors, although have provided a graphical representation, it is not clear about the income difference that was one of the aspects in the hypotheses/title.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Dr. Venkataramana Kandi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 May 17;18(5):e0285612. doi: 10.1371/journal.pone.0285612.r002

Author response to Decision Letter 0


17 Mar 2023

Ethics Statement:

This study used previously published data collected under a New York State Department of Health IRB. No original human research data were collected for this study and all death data were anonymized.

Editorial comments:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

The revised manuscript is formatted in accordance with PLOS ONE’s style requirements.

2. Ethics statement:

In this manuscript, we used published data which was collected under an IRB. This manuscript does not contain any original human research data. We have updated our Methods and Ethics Statement to clarify this.

Reviewer comments:

Reviewer #1: This paper estimated age-specific IFRs using data from a seroprevalence study conducted in New York City shortly after the peak of the spring 2020 epidemic. Then compared these to other IFR estimates that were based on relatively unbiased serosurveys to see if and how age-specific COVID-19 mortality patterns in New York City differed from other populations around the world. Finally, it correlated age-specific IFR estimates from different populations with measures of income and income inequality, which might reflect access to health care. This is helpful to provide some suggestions about the problem of the allocation of medical resources. The author is expected to make subsequent modifications according to the requirements and specifications of the journal.

We appreciate the positive comments from the reviewer and have revised the ms to meet the journal style requirements.

Reviewer #2: The infection fatality and the age of the patients have been described. However, the authors need to explain the infection fatality rate and its relation to the income inequality. The authors must segregate the countries referenced in to /based on income differences. The authors, although have provided a graphical representation, it is not clear about the income difference that was one of the aspects in the hypotheses/title.

We have revised the text to clarify the relationship between income and IFRs.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Junyuan Yang

27 Apr 2023

Age-specific SARS-CoV-2 infection fatality rates derived from serological data vary with income and income inequality

PONE-D-23-00943R1

Dear Dr. Richard,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Junyuan Yang

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1.Please correct the word "an" as "a" in line 96.

2.There is a problem: Is there less supporting data showing a correlation between income inequality and IFRs? The Figure 4 in this paper only tells us that death rates in some age groups(18-44 and 45-64) may be related to income inequality.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Acceptance letter

Junyuan Yang

4 May 2023

PONE-D-23-00943R1

Age-specific SARS-CoV-2 infection fatality rates derived from serological data vary with income and income inequality

Dear Dr. Rickards:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Junyuan Yang

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Age-specific infection fatality ratio (IFR) of COVID-19 (mean ± 95% CI) on an untransformed scale.

    Points are plotted at the midpoint of the age class on the x-axis, and slightly jittered along the x-axis facilitate presentation. Lines show age-specific IFRs for different populations, using confirmed-only COVID-19 deaths where possible. This study is represented in red, as “New York City”. IFR means and confidence intervals that estimate a value of 0 are represented as 0.001. The upper bound on the 90+ class for Sweden extends to 29.5% but is represented here as 20%.

    (PDF)

    S2 Fig. Infection fatality ratio (IFR) of COVID-19 plotted against the Gini index [41].

    Higher values of the Gini index represent higher levels of inequality. Fitted lines show significant relationships. Age classes include (a) 18–44, (b) 45–64, (c) 65–74, and (d) 75+. There were only three IFR estimates for the 0–17 age category so this age category was omitted from the plot.

    (PDF)

    S1 Table. Delay distributions and sources.

    The delays from symptom onset to case reporting [27] and from case reporting to death [28] are specific to New York City. See Perez-Saez et al. [11] for additional methods on delay distributions.

    (PDF)

    S2 Table. Exclusion criteria for global age-specific IFR comparisons.

    Serosurveys based on blood donors were not considered.

    (PDF)

    S3 Table. Seroprevalence and infection fatality rate (IFR) estimates in New York City for five age classes, using confirmed and probable COVID-19 deaths.

    The last column notes the percent increase in the IFR comparing confirmed deaths to confirmed and probable deaths.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All scripts and data files are available from a public Github repository at https://github.com/ChloeRickards/sars-cov-2-ifr-nyc.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES